Free Trial Free TrialFree Trial

More results...

Filter by Content types
Regulatory data
Regulatory reports
Market reports
News analysis

Alerts LATEST ALERTS

  • South Africa Committee shows mixed reactions to tobacco control bill…
  • Europe EC answers MEP question over possible conflict of interest…
  • Ukraine Resolution published on restricting minors’ access to heated tobacco websi ...
  • Russia State Duma passes bill to license production and distribution…
  • Bulgaria Heated tobacco flavours ban goes to consultation…
  • Spain MEPs call for EU regulation of novel tobacco products…
  • Canada Heated tobacco to be subjected to larger, rotating health warnings…
  • Vietnam National Assembly hears call for total ban on ‘new generation cigarettes’…
  • World WHO calls for ending subsidies for tobacco farming…
  • Europe Commissioner releases statement on World No Tobacco Day…
  • Czech Republic Bill addressing heated tobacco flavour ban is adopted…
  • Ukraine Advertising Act amendment bill adopted…
View all
News analysis

Reynolds submits last-minute PMTA application for its oral Velo Lozenges

Written by || 26th August 2020 || News analysis | Major brands | Modern oral | North America United States

Reynolds American has submitted a premarket tobacco product application (PMTA) to the US Food and Drug Administration (FDA) for its Velo nicotine lozenges to remain on the market after September ...

Benefits of subscription plans:

  • Stay informed of any legal and market change in the sector that impacts your organization
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Need help?

Contact a sales representative right now and don’t wait

Email us

Related contents

PMTA deadline put back as US judge grants FDA the extra time it asked for
Regulatory report: Q&A – US federal regulation of oral nicotine products
PMTA and MRTP: navigating the path to FDA approval for reduced-risk products
© 2023
TobaccoIntelligence does not provide legal, strategic or investment advice. Tamarind Media Limited, the publisher of TobaccoIntelligence,
does not accept any liability or responsibility for information or views published.